Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
CNBC's Jim Cramer connects the dots by reasoning that if the president were to act, he would pick a successor to Powell that would do his bidding.Economyread more
Tech trade organizations on Wednesday lashed back at a newly proposed bill by Sen. Josh Hawley, R-Mo., that would fundamentally alter the business models of tech companies...Technologyread more
Judy Shelton said in an interview that, if appointed to the Fed, she would want to lower interest rates all the way down to 0%.The Fedread more
Shoppers are "very nuanced in their expectations," Ron Johnson, the former CEO of J.C. Penney and the former senior vice president of Apple's retail division, said at CNBC's...Evolveread more
The winner will live in a centrally located apartment, receive a "salary" and explore the city to find what makes people there so happy.Liferead more
Hubert Joly announced in April he was ceding the chief executive spot to Corie Barry, a move that went into effect earlier this month. Joly will now be its executive chairman.Evolveread more
Beyond Meat has blown up. The plant-based meat company is now larger than 80 S&P 500 companies, including Macy's, Xerox and Mylan.Trading Nationread more
We've been given plenty of reasons to quit Facebook, including a new report that alleges disgusting working conditions at a company, Cognizant, it uses to employ contractors....Technologyread more
U.S. allies' drug pricing strategies are not sustainable for long-term success, and that's adversely leading to higher prescription costs at home and abroad, FDA Commissioner Dr. Scott Gottlieb told CNBC on Tuesday.
Europeans "do underpay relative to us for branded drugs and that's in part because they do put price controls and utilization restrictions on those drugs," Gottlieb said in a "Squawk Box " interview. "But they're overpaying relative to us on generic drugs."
"That's not a system for success in the long run," he argued. "So, I don't think they're set up for long-term success."
President Donald Trump on Friday criticized foreign allies, accusing them of paying less than the United States for prescription drugs while benefiting from American investment in research and drug development. He said he has directed U.S. Trade Representative Robert Lighthizer to make fixing this a top priority with every trading partner.
Gottlieb, who was praised by Trump during his speech Friday on how to lower prescription drug prices in the U.S., said the issue of "intellectual property appropriation" needs to be addressed on a trading level. "It's well above my pay grade in terms of having those discussions," Gottlieb added.
However, he said the U.S. also wants to make sure it adequately rewards companies that take on the risk of developing new drugs that may or may not work out.
"We do think the market-based system gives appropriate incentives and rewards for people to take the risk and innovate," he said. "The problem becomes when there's a lack of competition because of government rules that prevent the competition from taking place."
The idea behind the Trump plan is drug companies should raise prices overseas where governments subsidize costs and lower prices in the U.S.
However, not everyone was enthused about Trump targeting foreign countries.
Former Health and Human Services Secretary Tommy Thompson, who praised Trump for addressing the issue of high drug prices, told CNBC on Friday the president's possible strategy to push for increases in drug prices in foreign countries wouldn't work.
"Just raising the prices across the world isn't going to help America," said Thompson, who served as HHS secretary from 2001 to 2005 under President George W. Bush. "It's just going to increase prices for other people."